Melanoma News and Research

Latest Melanoma News and Research

Immunology professor receives 2014 Szent-Györgyi Prize for progress in cancer research from NFCR

Discovering key elements of immune system T cell biology and applying that knowledge to create a new way to treat cancer has earned Jim Allison, Ph.D., the 2014 Szent-Györgyi Prize for Progress in Cancer Research from the National Foundation for Cancer Research.

10 Feb 2014

Study provides extensive review of incidence, risk factors and characteristics of skin cancer in people of color

While people of color have a lower risk of developing skin cancer than Caucasians, they are not immune to the disease. In fact, skin cancer is often diagnosed at a more advanced stage in people of color, which can make it more difficult to treat.

6 Feb 2014

Poll shows only 35% of respondents likely to seek aggressive treatment to cancer

A national poll from the University of Utah's Huntsman Cancer Institute shows 34 percent of respondents would not seek genetic testing to predict their likelihood of developing a hereditary cancer - even if the cost of the testing was not an issue.

6 Feb 2014

Incyte enters into clinical trial collaboration agreement with Merck to evaluate safety of IDO1 inhibitor

Incyte Corporation (Nasdaq: INCY) announced today that it has entered into a clinical trial collaboration agreement with Merck, through a Merck subsidiary, to evaluate the safety and efficacy of Incyte's oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360, and Merck's investigational anti-PD-1 immunotherapy, MK-3475, in a Phase I/II study in previously treated metastatic and recurrent non-small cell lung cancer (NSCLC), and other advanced or metastatic cancers.

5 Feb 2014

Study: Ipilimumab with VEGF inhibitors may be potential option for melanoma patients

Among patients with advanced melanoma, presence of higher levels of the protein vascular endothelial growth factor (VEGF) in blood was associated with poor response to treatment with the immunotherapy ipilimumab, according to a study published in Cancer Immunology Research, a journal of the American Association for Cancer Research.

5 Feb 2014

Incidence of skin cancer increased nearly eightfold among middle-aged men and women

A new Mayo Clinic study found that among middle-aged men and women, 40 to 60 years old, the overall incidence of skin cancer increased nearly eightfold between 1970 and 2009, according to a study published in the January issue of Mayo Clinic Proceedings.

5 Feb 2014

Cancer specialist takes efforts to improve survival rates across Europe

Queen's University Belfast's world renowned cancer specialist, Professor Patrick Johnston, whose work has transformed cancer care in Northern Ireland, is now leading efforts to improve survival rates across Europe.

4 Feb 2014

NeoGenomics validates and launches series of NeoTYPE cancer profiling tests

NeoGenomics, Inc., a leading provider of cancer-focused genetic and molecular testing services, announced today that it has validated and launched a series of NeoTYPE cancer profiling tests covering 22 different categories of cancer. Each of these tests is designed to investigate the most common and actionable genomic abnormalities reported for that particular tumor.

30 Jan 2014

American Cancer Society, SU2C partner to fight against cancer

The American Cancer Society, the largest voluntary health organization in the world dedicated to eliminating cancer, and Stand Up To Cancer, the charitable initiative supporting groundbreaking research aimed at getting new treatments to patients in an accelerated timeframe, announced today an historic collaboration in the fight against cancer, which takes more than 585,000 lives in the U.S. each year and nearly 8 million worldwide.

30 Jan 2014

NIBIB-funded researchers develop microscopic technique to improve Mohs surgery

A common surgery for non-melanoma skin cancer, known as Mohs surgery typically achieves excellent results but can be a long process, as the surgeon successively removes the area of concern until the surrounding tissue is free of cancer.

29 Jan 2014

CU receives cooperative agreement to develop technological system to determine effects chemical agents

The University of Colorado Boulder has been awarded a cooperative agreement worth up to $14.6 million from the Defense Advanced Research Projects Agency (DARPA) to develop a new technological system to rapidly determine how drugs and biological or chemical agents exert their effects on human cells.

29 Jan 2014

Veterans with exposure to Agent Orange may be at higher risk for skin cancer

Vietnam War veterans with prior exposure to the herbicide Agent Orange may be at higher risk for certain types of skin cancer, suggests a report in the February issue of Plastic and Reconstructive Surgery-, the official medical journal of the American Society of Plastic Surgeons (ASPS).

29 Jan 2014

Response of brain tumors from SRS can indicate necessity of follow-up treatments

The response of a patient with metastatic brain tumors to treatment with stereotactic radiosurgery in the first six-to-twelve weeks can indicate whether follow-up treatments and monitoring are necessary, according to research conducted at the University of North Carolina.

28 Jan 2014

FDA meeting streamlines pathway to initial U.S. approval of Provectus's PV-10 oncology drug

Provectus Biopharmaceuticals, Inc. (PVCT), a development-stage oncology and dermatology biopharmaceutical company, today announced that it has received the official minutes from the Type C meeting held with the FDA's Division of Oncology Products 2 on December 16, 2013.

27 Jan 2014

Large-scale analysis of over 20 tumor types increases catalog of cancer genes by 25%

A landmark study across many cancer types reveals that the universe of cancer mutations is much bigger than previously thought. By analyzing the genomes of thousands of patients' tumors, a Broad Institute-led research team has discovered many new cancer genes - expanding the list of known genes tied to these cancers by 25 percent. Moreover, the study shows that many key cancer genes still remain to be discovered.

25 Jan 2014

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

Bristol-Myers Squibb Company today reported results for the fourth quarter and full year of 2013. The fourth quarter was highlighted by the company's announcement to sell its diabetes business as part of the continued evolution of its successful BioPharma strategy to a specialty care model. The company achieved important regulatory milestones in the quarter for Eliquis in the U.S., daclatasvir/asunaprevir in Japan, daclatasvir in Europe and Farxiga in the U.S. In addition, the company provided financial guidance for 2014.

24 Jan 2014

Selective FAK inhibition within endothelial cells prevents spontaneous tumor metastasis

A team of scientists, led by principal investigator David D. Schlaepfer, PhD, a professor in the Department of Reproductive Medicine at the University of California, San Diego School of Medicine, has found that a protein involved in promoting tumor growth and survival is also activated in surrounding blood vessels, enabling cancer cells to spread into the bloodstream.

24 Jan 2014

Personalized vaccine therapy contributes to increased survival rate in IL2-treated metastatic melanoma

Metastatic melanoma has a poor prognosis, but treatment with high-dose interleukin-2 (IL2) can extend survival. Now, a combination of IL2 therapy and activation of patients' immune systems using personalized vaccines made from their own tumor cells has been shown to improve survival rates even more than IL2 alone, according to a new article in Cancer Biotherapy and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

23 Jan 2014

MD Anderson collaborates with Johnson & Johnson to develop immunology-based cancer treatments

The University of Texas MD Anderson Cancer Center will collaborate with Johnson & Johnson Innovation, LLC, and its affiliate Janssen Biotech, Inc., to develop immunology-based cancer treatments through the MD Anderson Moon Shots Program immunotherapy platform.

23 Jan 2014

NCCC physicians use new gene sequencing equipment for testing abnormal DNA in cancerous tumor cells

Clinical laboratory experts and physicians at Dartmouth-Hitchcock Norris Cotton Cancer Center (NCCC) achieved 100 percent accuracy in testing for abnormal DNA in cancerous tumor cells with its new gene sequencing equipment and panels.

23 Jan 2014

Melanoma News and Research

Latest Melanoma News and Research

Immunology professor receives 2014 Szent-Györgyi Prize for progress in cancer research from NFCR

Study provides extensive review of incidence, risk factors and characteristics of skin cancer in people of color

Poll shows only 35% of respondents likely to seek aggressive treatment to cancer

Incyte enters into clinical trial collaboration agreement with Merck to evaluate safety of IDO1 inhibitor

Study: Ipilimumab with VEGF inhibitors may be potential option for melanoma patients

Incidence of skin cancer increased nearly eightfold among middle-aged men and women

Cancer specialist takes efforts to improve survival rates across Europe

NeoGenomics validates and launches series of NeoTYPE cancer profiling tests

American Cancer Society, SU2C partner to fight against cancer

NIBIB-funded researchers develop microscopic technique to improve Mohs surgery

CU receives cooperative agreement to develop technological system to determine effects chemical agents

Veterans with exposure to Agent Orange may be at higher risk for skin cancer

Response of brain tumors from SRS can indicate necessity of follow-up treatments

FDA meeting streamlines pathway to initial U.S. approval of Provectus's PV-10 oncology drug

Large-scale analysis of over 20 tumor types increases catalog of cancer genes by 25%

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

Selective FAK inhibition within endothelial cells prevents spontaneous tumor metastasis

Personalized vaccine therapy contributes to increased survival rate in IL2-treated metastatic melanoma

MD Anderson collaborates with Johnson & Johnson to develop immunology-based cancer treatments

NCCC physicians use new gene sequencing equipment for testing abnormal DNA in cancerous tumor cells

Innovation in neuroscience drug discovery - eBook eBook

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Evolving spectrophotometry for modern biopharma workflows

Melanoma News and Research

Latest Melanoma News and Research

Innovation in neuroscience drug discovery - eBook eBook

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Evolving spectrophotometry for modern biopharma workflows

Newsletters you may be interested in